Tamoxifen (TAM) is non-steroid triphenilethylene derivative with estrogen agonist-antagonist properties. In oncology it is used the tumoristatic TAM-action. Nowadays, TAM is the elective treatment for post- menopausal patients with breast cancer and positive lymphnodes as well as for pre-menopausal patients with negative nodes and positive estrogen receptors. It's acknowledged the efficiency of TAM in reducing the incidence of contralateral breast cancer up to a prevention use for high risk patients. After an exhaustive bibliographical review, the Authors introduce their study about TAM-induced genital pathology in women with breast cancer. 52 patients were enrolled in this study, treated between 1996-1997 by the Dept. of Gynecology of the Cancer Institute of Bari. The results, according to the literature, demonstrate that it should be better to follow closely the TAM- treated patients, moreover beginning with a preventive check of the > before the TAM-treatment and then to have periodic medical examinations to reduce to a minimum the risk of developing an even serious gynecologic TAM-correlated disease.
|Translated title of the contribution||Tamoxifen and female genital diseases. General considerations and clinical experience|
|Number of pages||6|
|Journal||Giornale Italiano di Ostetricia e Ginecologia|
|Publication status||Published - 1998|
ASJC Scopus subject areas
- Obstetrics and Gynaecology